Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day
BOTHELL, Wash. --(BUSINESS WIRE)--Feb. 6, 2019-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Guggenheim Healthcare Talks Idea Forum | Oncology Day on Thursday, February 14, 2019 at 2:00 p.m. Eastern Time . The presentation will be webcast live and
View HTML
Toggle Summary Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019
BOTHELL, Wash. --(BUSINESS WIRE)--Jan. 22, 2019-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 after the close of financial markets. Following the announcement, company management will
View HTML
Toggle Summary Seattle Genetics Announces Publication of North American Subgroup Data from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma
-North American Subgroup Analysis Trial Results Published in Clinical Cancer Research - -Data Consistent with ECHELON-1 Trial Outcome Showing Superior Clinical Activity of ADCETRIS in Combination with AVD when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma- BOTHELL, Wash.
View HTML
Toggle Summary Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
BOTHELL, Wash. --(BUSINESS WIRE)--Dec. 19, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the 37 th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 2:30 p.m. Pacific Time . Both the presentation and question and answer session that
View HTML
Toggle Summary Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
-Data Presented in Oral Session with Simultaneous Publication in The Lancet- -Randomized Phase 3 Clinical Trial Demonstrated ADCETRIS plus Chemotherapy Resulted in Superior Progression-Free Survival and Overall Survival Compared to a Standard of Care, CHOP- BOTHELL, Wash. & CAMBRIDGE, Mass.
View HTML
Toggle Summary Seattle Genetics Highlights Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at ASH Annual Meeting
-Data Continue to Show Superior Clinical Activity of ADCETRIS in Combination with AVD when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma- -Three-Year Progression-Free Survival Data Demonstrate ADCETRIS plus AVD Benefit of 83.1 Percent Compared to 76.0 Percent in ABVD Arm- -ADCETRIS in
View HTML
Toggle Summary Seattle Genetics Highlights Multiple Data Sets Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) at ASH Annual Meeting
-Initial Data Reported from Phase 2 Clinical Trial in Relapsed Primary Mediastinal Large B-Cell Lymphoma- -Results from Phase 1/2 Trial in Relapsed Hodgkin Lymphoma Continue to Support Combination Strategy- -Phase 2 Trial Evaluating Novel Combination Strategies in Children, Adolescents and Young
View HTML
Toggle Summary Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting
BOTHELL, Wash. --(BUSINESS WIRE)--Nov. 26, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the company will webcast an investor and analyst event on  Monday, December 3, 2018  during the 60th  American Society of Hematology  (ASH) Annual Meeting in San Diego, Calif. The program
View HTML
Toggle Summary Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
-First FDA-Approved Regimen in Frontline Peripheral T-Cell Lymphoma- -FDA Approval Based on Results from the Phase 3 ECHELON-2 Clinical Trial; Data to be Presented at the 2018 ASH Annual Meeting- -Application Approved Less Than Two Weeks After Submission Under FDA Real-Time Oncology Review Pilot
View HTML
Toggle Summary FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas
-Designation Based on Positive Phase 3 ECHELON-2 Trial Evaluating ADCETRIS in Frontline CD30-Expressing Peripheral T-Cell Lymphomas; Data to be Presented at Upcoming American Society of Hematology Annual Meeting in December- BOTHELL, Wash. --(BUSINESS WIRE)--Nov. 15, 2018-- Seattle Genetics, Inc.
View HTML